ОбзорГрафикПрофильОсновная статистикаФинансовые показателиНовости
Деривативы
TraderScreen

IPSEN S.A. PORT. EO 1/  FR0010259150  /

Lang & Schwarz
21.12.2024  13:03:44 Изменение 0.00 Объем сделки Бид13:03:44 Предложение13:03:44 Рыночная капитализация Дивидендная доходность Коэффициент Цена/Доход
107.80EUR 0.00% -
Оборот: -		 107.80Величина цены спроса: - 108.00Величина цены предложения: - 9.05 млрдEUR 1.11% 13.86
GlobeNewswire 26.07 Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and K...
GlobeNewswire 25.07 Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its ful...
GlobeNewswire 25.07 Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for ...
GlobeNewswire 11.07 Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug con...
GlobeNewswire 02.07 Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroend...
GlobeNewswire 10.06 Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primar...
GlobeNewswire 07.06 Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell eng...
GlobeNewswire 06.06 Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswire 05.06 Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with...
GlobeNewswire 02.05 Ipsen appoints Keira Driansky as EVP, President of North America
GlobeNewswire 24.04 Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines...
GlobeNewswire 22.04 Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological di...
GlobeNewswire 02.04 Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid t...
GlobeNewswire 13.02 Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreat...
GlobeNewswire 08.02 Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
GlobeNewswire 07.12.2023 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire 07.12.2023 Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid...
GlobeNewswire 13.11.2023 Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire 26.10.2023 Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidan...
GlobeNewswire 23.10.2023 Ipsen updates on E.U. Marketing Authorisation Application for odevixibat in Alagille syndrome
GlobeNewswire 03.10.2023 Ipsen updates on QM-1114 regulatory process
GlobeNewswire 04.09.2023 Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
GlobeNewswire 01.09.2023 Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
GlobeNewswire 21.08.2023 Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Caboza...
GlobeNewswire 16.08.2023 US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people w...